Priorities Emerged Which Will Shape Version 2.0 of IVI’s RA Model
Los Angeles, CA – September 20, 2018 — The Innovation and Value Initiative (IVI) today released public feedback and recommendations from its Technical Expert Panel (TEP), an objective third party comprised of five leaders in health economics, epidemiology, rheumatology, and patient communities, which the collaborative will use to shape version 2.0 of its Open-Source Value Platform (OSVP) model in Rheumatoid Arthritis (RA). The model examines outcomes and the relative value of drug therapies for patients with moderate to severe RA.
“The input during the comment period provided the technical expert panel with insights for how IVI’s RA model could better consider real-world data sources including the types of information that matter most to patients such as including patient reported outcomes,” said Dr. Jeff Curtis, the lead co-investigator on the TEP and Professor of Medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham (UAB). “It’s my hope that the rigorous, transparent and collaborative approach IVI has undertaken in building the RA model will ultimately help patients, rheumatologists, rheumatology groups that set best practices for RA management in the form of treatment guidelines and care pathways, payers and employers better evaluate treatment options and make the best decision for individual patients.”
Based on the public feedback received from a diverse range of stakeholders including patient advocacy organizations, academics, physicians, non-profit organizations, and life-science companies, and TEP deliberations and recommendations, IVI’s revised RA model, which has an anticipated public release in the second quarter of 2019, will:
- Seek out opportunities to augment the use of real-world data sources;
- Update both the systematic literature review and the network meta-analysis to ensure that the model reflects the most recent clinical evidence and domains of health relevant to both clinicians who treat RA, and patients;
- Expand model flexibility by adding more utility functions, allowing for treatment specific discontinuation, including additional outcomes based on evidence from peer-reviewed literature, and adding new treatment options such as biosimilars and recently approved treatments for moderate to severe RA.
“Models developed by IVI’s open-source value platform process are iterative and evolving as the science of value assessment advances, and as new evidence becomes available,” said Jennifer Bright, IVI’s executive director. “Since transparency and collaboration are vital to the value-assessment development process, IVI chooses to make available public and expert feedback to help foster trust amongst all value-assessment stakeholders.”
Schmidt Public Affairs
Telephone: (202) 285-0810
E-Mail: [email protected]
Follow IVI on Twitter: @IVI_health
Follow IVI on Facebook: @innovationandvalueinitiative
Follow IVI on LinkedIn: Innovation and Value Initiative
About the Innovation and Value Initiative
The Innovation and Value Initiative (IVI) is a collaboration among thought leaders in academia, patient advocacy organizations, payers, life sciences companies, providers, delivery systems, and other organizations. It was created to raise the level of discussion regarding value in health care and find common ground in the approach to measuring and rewarding value. IVI’s Strategic Advisory Panel includes experienced leaders from across the health care industry. Their role is to provide advice and ensure the credibility and rigor in the research and policy products and to ensure all parties have a voice in IVI activities.